聖湘生物(688289.SH):預計第一季淨利潤同比增長35.79%
格隆匯4月12日丨聖湘生物(688289.SH)公佈,預計2024年第一季度實現營業收入39,094.58萬元,與上年同期相比,將增加19,577.18萬元,同比增長100.31%。預計2024年第一季度實現歸屬於母公司所有者的淨利潤8,148.91萬元,與上年同期相比,將增加2,147.62萬元,同比增長35.79%。預計2024年第一季度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤7,433.56萬元,與上年同期相比,將增加7,075.88萬元,同比增長1,978.27%。
在國家全力推進生命健康產業高質量發展的背景下,公司憑藉早期前瞻性戰略規劃與投入佈局,在多賽道、多領域逐漸進入發力期,內生驅動與外延增長齊驅並進,展現出強勁的增長潛力。與此同時,公司積極捕捉並利用市場機遇,推動產品覆蓋的廣度與深度,面向醫院、疾控、社區、互聯網等場景提供更多解決方案,進一步提升產品性能、優化客户體驗,有效實現業務的協同增長,公司品牌影響力不斷提升,併為未來的可持續發展奠定了堅實的基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.